分子别名（Synonym）
CD19,B4,CVID3,MGC12802
表达区间及表达系统（Source）
Human CD19 (20-291), His Tag (CD9-H52H2) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).
Predicted N-terminus: Pro 20
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 32.0 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>90% as determined by reduced SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Human CD19 (20-291), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
活性（Bioactivity）-ELISA
Immobilized FMC63 MAb at 2 μg/mL (100 μL/well) can bind Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) with a linear range of 10-78 ng/mL (QC tested).
点击申请Protocol
活性（Bioactivity）-SPR
FMC63 MAb (mouse lgG2a) captured on CM5 chip via anti-mouse antibodies surface, can bind Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) with an affinity constant of 2.95 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
点击申请Protocol
CAR阳性表达率检测（Evaluation of CAR expression ）
FACS Analysis of anti-CD19 CAR Expression
293 cells were transfected with FMC63-scFv and RFP tag. 2x105 of the cells were first incubated with A. His Tag-protein control. B. Recombinant human CD19 (20-291), His Tag (Cat. No. CD9-H52H2, 10 μg/ml). C. Recombinant human CD19, His Tag (Cat. No. CD9-H52H2, 10 μg/ml) and FMC63 (Mouse anti-CD19 antibody). The FITC Anti-6xHis tag antibody was used to analyse with FACS. RFP was used to evaluate CAR (FMC63-scFv) expression and FITC was used to evaluate the binding activity of recombinant human CD19 (20-291), His Tag (Cat. No. CD9-H52H2).
点击申请Protocol
文献引用（Citations）
Compositions and methods for treatment of cancer
Authors: Lobb Roy, et al.
Journal: US20180142035A1 2018
Application: ELISA
背景（Background）
B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.
